Two of New Jersey’s pharmaceutical heavyweights are joining forces to secure the state’s position as a global leader in the next generation of affordable medicine.
Amneal Pharmaceuticals headquartered in Bridgewater, announced today a definitive agreement to acquire Piscataway-based Kashiv BioSciences in a transaction valued at over $1.1 billion. The deal includes $750 million in upfront cash and equity, with an additional $350 million in potential milestone payments.
The merger, expected to close in the second half of 2026, unites two companies located just 15 miles apart, creating a fully integrated “lab-to-patient” biosimilar platform right in the heart of New Jersey’s life sciences hub.
The acquisition is a strategic bet on the “loss-of-exclusivity” wave hitting the biotech industry. With over $300 billion in brand-name biologics expected to lose patent protection over the next decade, the combined entity aims to dominate the market for biosimilars—more affordable versions of complex biologic drugs.
By bringing Kashiv’s specialized manufacturing and R&D facilities in Piscataway under Amneal’s Bridgewater-led commercial umbrella, the company eliminates the need for overseas outsourcing, keeping high-tech jobs and production within New Jersey.
“Our companies share a deep-rooted commitment to high-quality medicines, and this transaction builds on more than ten years of partnership right here in New Jersey,” said Dr. Sandeep Athalye, CEO of Kashiv BioSciences.
The announcement comes as Amneal reports a powerhouse start to 2026. Alongside the acquisition news, the company released preliminary Q1 results showing a 4% revenue increase to $723 million and a staggering 217% jump in net income compared to the previous year.
Amneal’s co-CEOs, Chirag Patel and Chintu Patel, emphasized that the acquisition will accelerate growth and position the company as a leader in the next wave of affordable therapies. By combining capabilities, the company expects to launch multiple biosimilars annually and build a pipeline of more than 30 products by the end of the decade.
“Amneal delivered a very strong start to 2026… reflecting the strength of our diversified business,” the Patels said. “We are entering the Kashiv transaction from a position of strength, at a time when we see an extended period of accelerated growth ahead.”
